---
layout: post
title: "Notice of the Denial of a Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)"
date: 2026-02-04 21:50:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-03697
original_published: 2025-03-07 00:00:00 +0000
significance: 8.00
---

# Notice of the Denial of a Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)

**Published:** February 04, 2026 21:50 UTC
**Source:** Federal Register
**Original Published:** March 07, 2025 00:00 UTC
**Document Number:** 2025-03697

## Summary

The Food and Drug Administration (FDA) is announcing the availability of the decision to deny a request for a hearing regarding the proposal of the Center for Drug Evaluation and Research (CDER) to refuse to approve the supplemental new drug application (sNDA) 205677- 012, submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), for the treatment of insomnia characterized by difficulties with sleep initiation. The decision, which also refuses approval of sNDA 205677-012, is available in the docket identified by the number in the heading of this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/03/07/2025-03697/notice-of-the-denial-of-a-hearing-request-regarding-a-proposal-to-refuse-to-approve-a-supplemental)
- API: https://www.federalregister.gov/api/v1/documents/2025-03697

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
